Current aims of management of rheumatoid arthritis (RA) patients are remission of the disease, or at least, achievement of its low activity. Early diagnosis of RA is highly important, allowing immediate start of therapy with classic disease modifying anti-rheumatic drugs (DMARDs). However, that kind of therapy does not guarantee achievement of therapeutic goals in all patients. In case of failure, introduction of biological drugs is necessary Despite a significant progress noted in RA therapy since introduction of tumour necrosis factor alpha (TNF-alpha) inhibitors several years ago, also that scheme failed to be effective in all cases of RA. New biological drugs characterised by a different mechanism of action than TNF-alpha inhibitors: Tocilizumab, Rituximab and Abatacept, are hope for non-responders to previous therapies.